Cargando…

Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial

BACKGROUND: A previous phase IV trial revealed sex as a potential effect modifier of MUSKARDIA efficacy in stable coronary artery disease (CAD). OBJECTIVE: To assess the clinical effect of MUSKARDIA as a supplemental treatment to optimal medical therapy (OMT) in stable CAD cases. METHODS: This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Haiming, Zhou, Jingmin, Ma, Changsheng, Ji, Fusui, Wu, Yang, Zhao, Yulan, Qian, Jun, Wang, Xiaolong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651060/ https://www.ncbi.nlm.nih.gov/pubmed/36386372 http://dx.doi.org/10.3389/fcvm.2022.1002400

Ejemplares similares

Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
por: Zhou, Jingmin, et al.
Publicado: (2023)

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial
por: Ge, Jun-Bo, et al.
Publicado: (2021)

Protective Effect of Shexiang Baoxin Pill on Myocardial Ischemia/Reperfusion Injury in Patients With STEMI
por: Qin, Haixia, et al.
Publicado: (2021)

Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow
por: Guo, Hongxin, et al.
Publicado: (2022)

A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases
por: Fang, Hai-Yang, et al.
Publicado: (2017)

Effects of Shexiang Baoxin Pill for Coronary Microvascular Function: A Systematic Review and Meta-Analysis
por: Wang, Mengxi, et al.
Publicado: (2021)

Shexiang Baoxin Pill for Acute Myocardial Infarction: Clinical Evidence and Molecular Mechanism of Antioxidative Stress
por: Guo, Jianbo, et al.
Publicado: (2021)

Shexiang Baoxin Pills Inhibited Proliferation and Migration of Human Coronary Artery Smooth Muscle Cells via PI3K/AKT/mTOR Pathway
por: Hua, Lei, et al.
Publicado: (2021)

Metabolomic Strategy for Studying the Intervention and the Synergistic Effects of the Shexiang Baoxin Pill for Treating Myocardial Infarction in Rats
por: Xiang, Li, et al.
Publicado: (2013)

Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria
por: Wei, Dan, et al.
Publicado: (2018)

Shexiang Baoxin Pills as an Adjuvant Treatment for Chronic Heart Failure: A System Review and Meta-Analysis
por: Dong, Taiwei, et al.
Publicado: (2018)

Shexiang Baoxin Pills for Coronary Heart Disease in Animal Models: Preclinical Evidence and Promoting Angiogenesis Mechanism
por: Zhang, Ke-Jian, et al.
Publicado: (2017)

Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy
por: Yang, Liu-qing, et al.
Publicado: (2019)

Efficacy of Shexiang Baoxin Pills for the treatment of unstable angina pectoris: Protocol of systemic review and meta-analysis
por: Chen, Huadong, et al.
Publicado: (2019)

Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases
por: Lu, Li, et al.
Publicado: (2018)

Antidepressant and anxiolytic effects of the proprietary Chinese medicine Shexiang Baoxin pill in mice with chronic unpredictable mild stress
por: Zhou, Xi-Dan, et al.
Publicado: (2018)

Efficacy and safety of Shexiang Baoxin Pill for stable coronary artery disease: A systematic review and meta-analysis of 42 randomized controlled trials
por: Wei, Jingjing, et al.
Publicado: (2022)

Single-nucleus ribonucleic acid-sequencing and spatial transcriptomics reveal the cardioprotection of Shexiang Baoxin Pill (SBP) in mice with myocardial ischemia-reperfusion injury
por: Lin, Wenyong, et al.
Publicado: (2023)

Shexiang Baoxin Pill Alleviates the Atherosclerotic Lesions in Mice via Improving Inflammation Response and Inhibiting Lipid Accumulation in the Arterial Wall
por: Lu, Li, et al.
Publicado: (2019)

Shexiang Baoxin Pill, a Traditional Chinese Herbal Formula, Rescues the Cognitive Impairments in APP/PS1 Transgenic Mice
por: Hu, Wei-Hui, et al.
Publicado: (2020)

Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
por: Wei, Jingjing, et al.
Publicado: (2021)

Block Matching Pyramid Algorithm-Based Analysis on Efficacy of Shexiang Baoxin Pills Guided by Echocardiogram (ECG) on Patients with Angina Pectoris in Coronary Heart Disease
por: Gao, Junqing, et al.
Publicado: (2021)

Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial
por: Tian, Pan-pan, et al.
Publicado: (2018)

Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis
por: Wen, Jianxia, et al.
Publicado: (2018)

Efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction: A single-center, double-blind, randomized controlled trial
por: Yang, Yan, et al.
Publicado: (2021)

Shexiang Baoxin Pills Could Alleviate Isoproterenol-Induced Heart Failure Probably through its Inhibition of CaV1.2 Calcium Channel Currents
por: Wu, Jianwei, et al.
Publicado: (2022)

Shexiang Baoxin Pill, a Formulated Chinese Herbal Mixture, Induces Neuronal Differentiation of PC12 Cells: A Signaling Triggered by Activation of Protein Kinase A
por: Xu, Miranda Li, et al.
Publicado: (2019)

Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial
por: Liu, Si-pei, et al.
Publicado: (2022)

Shexiang Baoxin Pill, a Proprietary Multi-Constituent Chinese Medicine, Prevents Locomotor and Cognitive Impairment Caused by Brain Ischemia and Reperfusion Injury in Rats: A Potential Therapy for Neuropsychiatric Sequelae of Stroke
por: Qin, Zong-Shi, et al.
Publicado: (2021)

Efficacy of Shexiang Tongxin Dropping Pills in a Swine Model of Coronary Slow Flow
por: Bai, Yupeng, et al.
Publicado: (2022)

Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro
por: Qi, Jianyong, et al.
Publicado: (2017)

Protective effects of Shexiang Tongxin Dropping Pill on pituitrin-induced acute myocardial ischemia in rats
por: Lin, Shan, et al.
Publicado: (2017)

Shexiang Tongxin Dropping Pill Improves Peripheral Microvascular Blood Flow via Cystathionine-γ-Lyase
por: Zhang, Yanda, et al.
Publicado: (2019)

LC-MS-based metabolomics reveals the mechanism of anti-gouty arthritis effect of Wuwei Shexiang pill
por: Lang, Jirui, et al.
Publicado: (2023)

Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients with normal fractional flow reserve and coronary microvascular disease: A study protocol
por: Lu, Yanli, et al.
Publicado: (2020)

Shexiang-Wulong Pills Attenuate Rheumatoid Arthritis by Alleviating Inflammation in a Mouse Model of Collagen-Induced Arthritis
por: Zhang, Zhihui, et al.
Publicado: (2019)

Mechanism Investigation of Wuwei Shexiang Pills on Gouty Arthritis via Network Pharmacology, Molecule Docking, and Pharmacological Verification
por: Lang, Jirui, et al.
Publicado: (2022)

Exploring the mechanism of Shexiang Tongxin dropping pill in the treatment of microvascular angina through network pharmacology and molecular docking
por: Chang, Chen, et al.
Publicado: (2022)

Qualitative and Quantitative Analysis of the Major Constituents in Shexiang Tongxin Dropping Pill by HPLC-Q-TOF-MS/MS and UPLC-QqQ-MS/MS
por: Chen, Daxin, et al.
Publicado: (2015)

Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance
por: Chen, Weiyao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6t938jh8b2iilqbc8rbgba1h7l